尽管靶向和免疫治疗已成为晚期驱动基因阳性/阴性非小细胞肺癌(NSCLC)的一线标准治疗,然而,耐药后的患者管理仍是临床实践面临的挑战和难题。在去年ESMO大会上,TROP2 ADC Dato-DXd的首个III期临床试验TROPION-Lung01研究重磅亮相,成为首个针对...
Designed using Daiichi Sankyo’s proprietary DXd ADC technology to target and deliver a cytotoxic payload inside cancer cells that express a specific cell surface antigen, each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor...
Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candi...
two important trials that demonstrate the strength and potential of our DXd ADC technology in creating transformative medicines for patients with cancer." Following SABCS, Daiichi Sankyo will hold its annual R&D Day for investors and analysts on Tuesday, December 14, 2021 at 5:30 pm EST/Wednesday...
Designed using Daiichi Sankyo’s proprietary DXd ADC technology, each ADC targets and delivers a cytotoxic payload inside cancer cells that express a specific cell surface antigen. Each ADC consists of a monoclonal antibody attached to...
Vice President Oncology R&D and Head, Alpha Portfolio, Daiichi Sankyo. “Based on preclinical assessments, biomarker research and the demonstrated portability of our DXd ADC technology, we believe that DS-6157 could potentially play a major role in the...
Each ADC is designed using Daiichi Sankyo’s proprietary DXd ADC technology to target and deliver cytotoxic payload inside cancer cells that express a specific cell surface antigen. Each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan der...
“With DS-6000, we have applied our innovative DXd ADC technology to a promising molecular target, CDH6, and it has potential to serve as a new treatment modality for patients with renal cell or ovarian cancer,” said Arnaud Lesegretain, Vice Preside...
德曲妥珠单抗(Trastuzumab deruxtecan、T-DXd、Enhertu、优赫得、DS-8201)是一种新型的抗体偶联药物(ADC)。它巧妙地将靶向HER2的抗体与高效的细胞毒性药物连接在一起,可同时杀伤目标肿瘤细胞和邻近的肿瘤细胞。其作用机制就像一枚精准制导的智能武器,能够特异性地识别并结合HER2阳性的肿瘤细胞,然后将细胞毒性药物精准输...
Each ADC is designed using Daiichi Sankyo’s proprietary DXd ADC technology to target and deliver cytotoxic payload inside cancer cells that express a specific cell surface antigen. Each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan der...